Aminosalicylic acid: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) |
||
| Line 27: | Line 27: | ||
'''| [[Aminosalicylic acid clinical studies|Clinical Studies]]''' | '''| [[Aminosalicylic acid clinical studies|Clinical Studies]]''' | ||
'''| [[Aminosalicylic acid dosage and administration|Dosage and Administration]]''' | '''| [[Aminosalicylic acid dosage and administration|Dosage and Administration]]''' | ||
'''| [[Aminosalicylic acid how supplied|How Supplied]]''' | '''| [[Aminosalicylic acid how supplied|How Supplied]]''' | ||
'''| [[Aminosalicylic acid labels and packages|Labels and Packages]]''' | '''| [[Aminosalicylic acid labels and packages|Labels and Packages]]''' | ||
Revision as of 21:44, 25 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: ; Chetan Lokhande, M.B.B.S [2]
Overview
Aminosalicylic acid (also known as para-aminosalicylic acid, p-aminosalicylic acid or 4-aminosalicylic acid; abbreviated 4-ASA, or PAS) is an antibiotic used to treat tuberculosis. It has been use for over forty years in the treatment of inflammatory bowel diseases (IBDs), where it has shown greater potency in Crohn's disease. It is thought to act via NF-κB (nuclear factor-kappa B) inhibition and free radical scavenging.
Aminosalicylic acid is sold in the United States by Jacobus Pharmaceutical as PASER®. Mesalazine (5-aminosalicylic acid) is a closely related compound that also has medical uses.
Category
Antimycobacterial
US Brand Names
PASER®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages